• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by OrthoPediatrics Corp. (Amendment)

    8/17/22 4:43:00 PM ET
    $KIDS
    Medical/Dental Instruments
    Health Care
    Get the next $KIDS alert in real time by email
    SC 13D/A 1 d342795dsc13da.htm SC 13D/A SC 13D/A

     

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

     

    SCHEDULE 13D

    [Rule 13d-101]

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 204.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO

    § 240.13d-2(a)

    (Amendment No. 1)

     

     

    OrthoPediatrics Corp.

    (Name of Issuer)

    Common Stock, par value $0.00025 per share

    (Title of Class of Securities)

    68752L100

    (CUSIP Number)

     

    Cathy A. Birkeland, Esq.

    Alexa M. Berlin, Esq.

    Latham & Watkins LLP

    330 N. Wabash Avenue, Suite 2800

    Chicago, Illinois 60611

    (312) 876-7700

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    August 10, 2022

    (Date of Event which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.  ☐

    (Continued on following pages)

    (Page 1 of 10 Pages)

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 68752L100    13D    Page 2 of 10 Pages

     

      1.    

      Names of Reporting Persons

     

      Squadron Capital LLC

      2.  

      Check the Appropriate Box if a Member of a Group

      (a)  ☐        (b)  ☒

     

      3.  

      SEC Use Only

     

      4.  

      Source of Funds

     

      OO

      5.  

      Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

      ☐

      6.  

      Citizenship or Place of Organization

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7.     

      Sole Voting Power

     

      0

         8.   

      Shared Voting Power

     

      5,376,764

         9.   

      Sole Dispositive Power

     

      0

       10.   

      Shared Dispositive Power

     

      6,901,7641

    11.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      6,901,7641

    12.  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares

     

      ☐

    13.  

      Percent of Class Represented by Amount in Row (11)

     

      30.1% 2

    14.  

      Type of Reporting Person

     

      OO

     

     

    1 

    Includes 1,525,000 shares of common stock, par value $0.00025 per share, of the Issuer (“Common Stock”) issuable to SC LLC (as defined in this Schedule 13D) upon exercise of non-voting Pre-Funded Warrants (defined below) purchased by SC LLC as part of the Issuer’s August 2022 Public Offering (defined below).

    2 

    Based on (i) 20,278,189 shares of Common Stock outstanding as of August 2, 2022, reported in the Issuer’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, plus (ii) 1,091,250 shares of Common Stock issued in connection with the Issuer’s August 2022 Public Offering (including the underwriters’ exercise of their option to purchase additional shares in full), plus (iii) 1,525,000 shares of Common Stock issuable to SC LLC upon exercise of non-voting Pre-Funded Warrants purchased by SC LLC as part of the Issuer’s August 2022 Public Offering.


    CUSIP No. 68752L100    13D    Page 3 of 10 Pages

     

      1.    

      Names of Reporting Persons

     

      Squadron Capital Holdings LLC

      2.  

      Check the Appropriate Box if a Member of a Group

      (a)  ☐        (b)  ☒

     

      3.  

      SEC Use Only

     

      4.  

      Source of Funds

     

      OO

      5.  

      Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

      ☐

      6.  

      Citizenship or Place of Organization

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7.     

      Sole Voting Power

     

      0

         8.   

      Shared Voting Power

     

      5,376,764

         9.   

      Sole Dispositive Power

     

      0

       10.   

      Shared Dispositive Power

     

      6,901,7641

    11.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      6,901,7641

    12.  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares

     

      ☐

    13.  

      Percent of Class Represented by Amount in Row (11)

     

      30.1% 2

    14.  

      Type of Reporting Person

     

      OO

     

     

    1 

    Includes 1,525,000 shares of Common Stock issuable to SC LLC upon exercise of non-voting Pre-Funded Warrants purchased by SC LLC as part of the Issuer’s August 2022 Public Offering.

    2 

    Based on (i) 20,278,189 shares of Common Stock outstanding as of August 2, 2022, reported in the Issuer’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, plus (ii) 1,091,250 shares of Common Stock issued in connection with the Issuer’s August 2022 Public Offering (including the underwriters’ exercise of their option to purchase additional shares in full), plus (iii) 1,525,000 shares of Common Stock issuable to SC LLC upon exercise of non-voting Pre-Funded Warrants purchased by SC LLC as part of the Issuer’s August 2022 Public Offering.


    CUSIP No. 68752L100    13D    Page 4 of 10 Pages

     

      1.    

      Names of Reporting Persons

     

      Jennifer N. Pritzker

      2.  

      Check the Appropriate Box if a Member of a Group

      (a)  ☐        (b)  ☒

     

      3.  

      SEC Use Only

     

      4.  

      Source of Funds

     

      OO

      5.  

      Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

      ☐

      6.  

      Citizenship or Place of Organization

     

      United States

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7.     

      Sole Voting Power

     

      10,900

         8.   

      Shared Voting Power

     

      5,380,571

         9.   

      Sole Dispositive Power

     

      10,900

       10.   

      Shared Dispositive Power

     

      6,905,5711

    11.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      6,916,4711

    12.  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares

     

      ☐

    13.  

      Percent of Class Represented by Amount in Row (11)

     

      30.2% 2

    14.  

      Type of Reporting Person

     

      IN

     

     

    1 

    Includes 1,525,000 shares of Common Stock issuable to SC LLC upon exercise of non-voting Pre-Funded Warrants purchased by SC LLC as part of the Issuer’s August 2022 Public Offering.

    2 

    Based on (i) 20,278,189 shares of Common Stock outstanding as of August 2, 2022, reported in the Issuer’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, plus (ii) 1,091,250 shares of Common Stock issued in connection with the Issuer’s August 2022 Public Offering (including the underwriters’ exercise of their option to purchase additional shares in full), plus (iii) 1,525,000 shares of Common Stock issuable to SC LLC upon exercise of non-voting Pre-Funded Warrants purchased by SC LLC as part of the Issuer’s August 2022 Public Offering.


    CUSIP No. 68752L100    13D    Page 5 of 10 Pages

     

      1.    

      Names of Reporting Persons

     

      David R. Pelizzon

      2.  

      Check the Appropriate Box if a Member of a Group

      (a)  ☐        (b)  ☒

     

      3.  

      SEC Use Only

     

      4.  

      Source of Funds

     

      OO

      5.  

      Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

      ☐

      6.  

      Citizenship or Place of Organization

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7.     

      Sole Voting Power

     

      24,816

         8.   

      Shared Voting Power

     

      5,376,764

         9.   

      Sole Dispositive Power

     

      22,016

       10.   

      Shared Dispositive Power

     

      6,901,7641

    11.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      6,926,5801

    12.  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares

     

      ☐

    13.  

      Percent of Class Represented by Amount in Row (11)

     

      30.3% 2

    14.  

      Type of Reporting Person

     

      IN

     

     

    1 

    Includes 1,525,000 shares of Common Stock issuable to SC LLC upon exercise of non-voting Pre-Funded Warrants purchased by SC LLC as part of the Issuer’s August 2022 Public Offering.

    2 

    Based on (i) 20,278,189 shares of Common Stock outstanding as of August 2, 2022, reported in the Issuer’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, plus (ii) 1,091,250 shares of Common Stock issued in connection with the Issuer’s August 2022 Public Offering (including the underwriters’ exercise of their option to purchase additional shares in full), plus (iii) 1,525,000 shares of Common Stock issuable to SC LLC upon exercise of non-voting Pre-Funded Warrants purchased by SC LLC as part of the Issuer’s August 2022 Public Offering.


    CUSIP No. 68752L100    13D    Page 6 of 10 Pages

     

    EXPLANATORY NOTE: This Amendment No. 1 to Schedule 13D (“Amendment No. 1”) relates to the shares of common stock, $0.00025 par value per share (“Common Stock”), of OrthoPediatrics Corp., a Delaware corporation (the “Issuer”), which has its principal executive offices at 2850 Frontier Drive, Warsaw, Indiana 46582. This Amendment No. 1 amends and supplements, as set forth below, the Schedule 13D filed by the Reporting Persons with respect to the Issuer on March 18, 2021 (the “Original Schedule 13D”). The Original Schedule 13D, as amended and supplemented by Amendment No. 1, is referred to as the “Schedule 13D.” All capitalized terms not otherwise defined herein have the meanings ascribed to them in the Schedule 13D. The Schedule 13D is amended and supplemented by adding the information contained herein. Only those items amended are reported herein.

    Item 3. Source and Amount of Funds or Other Consideration.

    Item 3 of the Schedule 13D is amended and supplemented as follows:

    The Issuer used proceeds from its August 2022 Public Offering to, among other things, repay approximately $31.0 million of outstanding indebtedness under its loan agreement with SC LLC. SC LLC purchased the Pre-Funded Warrants using the funds received in connection with such repayment of indebtedness as well as cash on hand.

    Item 4. Purpose of Transaction.

    Item 4 of the Schedule 13D is amended and supplemented as follows:

    On August 10, 2022, SC LLC submitted to Piper Sandler & Co. (“Piper Sandler”) and Stifel, Nicolaus & Company, Incorporated (“Stifel”) a non-binding indication of interest to potentially acquire up to $90.0 million of Pre-Funded Warrants of the Issuer being marketed by Piper Sandler and Stifel at such time, at the public offering price (less $0.00025 per pre-funded warrant, which is their exercise price) and on the same terms as other purchasers in the August 2022 Public Offering. The non-binding indication of interest did not constitute a commitment, a contract to provide a commitment or an offer to enter into a contract regarding any transaction. Any binding obligation on SC LLC to purchase any Pre-Funded Warrants was subject to a number of conditions.

    The August 2022 Equity Offering closed on August 15, 2022. Pursuant to the August 2022 Equity Offering, SC LLC acquired 1,525,000 non-voting Pre-Funded Warrants.


    CUSIP No. 68752L100    13D    Page 7 of 10 Pages

     

    Item 5. Interest in Securities of the Issuer

    Item 5 of the Schedule 13D is amended and restated in its entirety as follows:

    (a) – (b) The table below sets forth, as of the date hereof, the beneficial ownership of shares of Common Stock for each of the Reporting Persons, based on (i) 20,278,189 shares of Common Stock outstanding as of August 2, 2022, reported in the Issuer’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, plus (ii) 1,091,250 shares of Common Stock issued in connection with the Issuer’s August 2022 Public Offering (including the underwriters’ exercise of their option to purchase additional shares in full), plus (iii) 1,525,000 shares of Common Stock issuable to SC LLC upon exercise of non-voting Pre-Funded Warrants purchased by SC LLC as part of the Issuer’s August 2022 Public Offering.

     

    Reporting Person   

    Amount

    beneficially

    owned

       

    Percent

    of class:

        Sole
    power
    to vote
    or to
    direct
    the vote:
         Shared
    power to
    vote or to
    direct the
    vote:
        

    Sole
    power to
    dispose or
    to direct
    the
    disposition

    of:

        

    Shared

    power to

    dispose or

    to direct

    the

    disposition

    of:

     

    Squadron Capital LLC

         6,901,764 1      30.1 %      —          5,376,764        —          6,901,764 1 

    Squadron Capital Holdings LLC

         6,901,764 1      30.1 %      —          5,376,764        —          6,901,764 1 

    Jennifer N. Pritzker

         6,916,471 1      30.2 %      10,900        5,380,571        10,900        6,905,571 1 

    David R. Pelizzon

         6,926,580 1      30.3 %      24,816        5,376,764        22,016        6,901,764 1 

     

    1

    Includes 1,525,000 shares of Common Stock issuable to SC LLC upon exercise of the non-voting Pre-Funded Warrants.

    SC LLC is a manager-managed limited liability company and, as of the date hereof, directly holds 5,376,764 shares of Common Stock and 1,525,000 shares of Common Stock issuable to it upon exercise of the non-voting Pre-Funded Warrants. The voting and investment decisions of SC LLC are made by its managing committee, consisting of Ms. Pritzker and Mr. Pelizzon. In such capacity each of Ms. Pritzker and Mr. Pelizzon may, for the purposes hereof, be deemed to beneficially own the shares of Common Stock held directly by SC LLC.

    Mr. Pelizzon directly holds 22,016 shares of Common Stock and 2,800 restricted shares that Mr. Pelizzon has the ability to vote but is restricted from transferring until their vesting date.

    Ms. Pritzker directly and/or jointly holds 10,900 shares of Common Stock. Ms. Pritzker may also, for the purposes hereof, be deemed to beneficially own (i) 500 shares of Common Stock held directly by the Pritzker Military Museum and Library, for which she is the sole member, (ii) 1,300 shares of Common Stock held directly by the Tawani Foundation, for which she is the sole member, (iii) 1,300 shares of Common Stock held by the Pritzker Military Foundation, for which she is the sole member, and (iv) 707 shares of Common Stock held directly by her spouse.

    SCH LLC is a manager-managed limited liability company and the controlling member of SC LLC, and in such capacity may be deemed to beneficially own the shares of Common Stock held directly by SC LLC. The voting and investment decisions of SCH LLC are made by its managing committee, consisting of Mary Parthe, David Pelizzon and Michelle Nakfoor. The members of the managing committee of SCH LLC disclaim beneficial ownership as a result of serving as members of the managing committee.

    (c) Except as otherwise set forth in this Amendment No. 1, to the best knowledge of the Reporting Persons, none of the Reporting Persons nor any other person listed on Schedule A hereto has effected any transaction in the Common Stock during the past 60 days.

    (d) To the best knowledge of the Reporting Persons, no other person has the right to receive dividends from, or the proceeds from the sale of, securities listed in this Item 5.

    (e) Not applicable.


    CUSIP No. 68752L100    13D    Page 8 of 10 Pages

     

    Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.

    Item 6 of the Schedule 13D is amended and supplemented as follows:

    August 2022 Equity Offering

    On August 10, 2022, the Issuer announced that it was offering (the “August 2022 Equity Offering”) (i) shares of Common Stock to the public and (ii) Pre-Funded Warrants to purchase shares of Common Stock to SC LLC, which beneficially owned shares of Common Stock in excess of the notification threshold of the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”). The August 2022 Equity Offering closed on August 15, 2022. Pursuant to the August 2022 Equity Offering, SC LLC acquired 1,525,000 non-voting Pre-Funded Warrants for a purchase price of $54.99975 per Pre-Funded Warrant (the price per share at which the Common Stock was sold to the public in the August 2022 Equity Offering minus $0.00025, which is the exercise price of each Pre-Funded Warrant), for an aggregate purchase price of approximately $83.9 million. The Issuer used proceeds from its August 2022 Public Offering to, among other things, repay approximately $31.0 million of outstanding indebtedness under its loan agreement with SC LLC. SC LLC purchased the Pre-Funded Warrants using the funds received in connection with such repayment of indebtedness as well as cash on hand.

    Form of Pre-Funded Warrant (“Pre-Funded Warrants”)

    The Pre-Funded Warrants were issued as individual warrant agreements and have an exercise price of $0.00025 per share. The exercise price and number of shares of the Issuer’s Common Stock issuable upon exercise of the Pre-Funded Warrants is subject to appropriate adjustment in the event of certain stock dividends and distributions or similar events affecting the Issuer’s Common Stock, as well as upon any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction, to the Issuer’s stockholders. The exercise price of the Pre-Funded Warrants will not be adjusted below the par value of the Issuer’s Common Stock.

    The Pre-Funded Warrants are exercisable, at the option of SC LLC, in whole or in part, by delivering to the Issuer a duly executed exercise notice accompanied by payment in full for the number of shares of the Issuer’s Common Stock purchased upon such exercise (except in the case of a cashless exercise as discussed below). No fractional shares of Common Stock will be issued in connection with the exercise of a Pre-Funded Warrant. In lieu of fractional shares, the Issuer will either pay a cash adjustment in respect of such final fractions in an amount equal to such fraction multiplied by the exercise price or round up to the nearest whole share.


    CUSIP No. 68752L100    13D    Page 9 of 10 Pages

     

    In lieu of making the cash payment otherwise contemplated to be made to the Issuer upon such exercise in payment of the aggregate exercise price, SC LLC may elect instead to receive upon such exercise (either in whole or in part) the net number of shares of Common Stock determined according to a formula set forth in the Pre-Funded Warrants.

    The Pre-Funded Warrants may not be exercised by SC LLC to the extent that it, together with its affiliates that report together as a group under the beneficial ownership rules, upon giving effect to such exercise, would cause SC LLC to acquire beneficial ownership of shares of the Issuer’s Common Stock (together with all other equity of the Issuer owned by SC LLC at such time) with a value of or in excess of the HSR Act notification threshold applicable to SC LLC (absent an applicable exemption to filing a notice and report form under the HSR Act). In addition, once the HSR Act waiting period on a notification expires or the exercise otherwise becomes exempt from the notification requirements thereunder, SC LLC is required to exercise the Pre-Funded Warrants pursuant to their terms within five business days.

    Subject to applicable laws, the Pre-Funded Warrants may be offered for sale, sold, transferred or assigned without the Issuer’s consent.

    Upon the consummation of a fundamental transaction (as described in the Pre-Funded Warrants, and generally including any reorganization, recapitalization or reclassification of the Issuer’s Common Stock, the sale, transfer or other disposition of all or substantially all of the Issuer’s assets, the Issuer’s consolidation or merger with or into another person, the acquisition of more than 50% of the voting power of the Issuer’s outstanding capital stock, or any person or group becoming the beneficial owner of 50% or more of the voting power of the Issuer’s outstanding capital stock), SC LLC will be entitled to receive, upon exercise of the Pre-Funded Warrants, the same amount and kind of securities, cash or property as SC LLC would have been entitled to receive upon the occurrence of such fundamental transaction if it had been, immediately prior to such fundamental transaction, the holder of the number of shares of Common Stock then issuable upon exercise in full of such Pre-Funded Warrant without regard to any limitations on exercise contained therein.

    Except by virtue of SC LLC’s ownership of shares of the Issuer’s Common Stock, SC LLC does not, as the holder of a Pre-Funded Warrant, have the rights or privileges of a holder of the Issuer’s Common Stock, including any voting rights, until it exercises the Pre-Funded Warrant. Notwithstanding the foregoing, SC LLC, as the holder of Pre-Funded Warrants, will receive the benefit of any dividends declared and paid by the Issuer, as if it had exercised such Pre-Funded Warrants, upon their ultimate exercise.

    The foregoing description of the Form of Pre-Funded Warrant does not purport to be complete and is qualified in its entirety by reference to the Form of Pre-Funded Warrant, a copy of which is filed as Exhibit 5 to this Amendment No. 1 and is incorporated by reference in its entirety into this Item 6.


    CUSIP No. 68752L100    13D    Page 10 of 10 Pages

     

    Lock-Up Agreement

    In connection with the August 2022 Equity Offering, on August 9, 2022, SC LLC entered into a lock-up agreement (the “Lock-Up Agreement”) with the underwriters in the August 2022 Equity Offering pursuant to which SC LLC, subject to certain exceptions, for a period of 90 days after the date of August 2022 Equity Offering final prospectus, may not, without the prior written consent of Stifel, (i) offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, make any short sale or otherwise transfer or dispose of, directly or indirectly, any shares of the Issuer’s Common Stock or any securities convertible into, exercisable or exchangeable for or that represent the right to receive the Issuer’s Common Stock (including without limitation, Common Stock which may be deemed to be beneficially owned by the undersigned in accordance with the rules and regulations of the Securities and Exchange Commission and securities which may be issued upon exercise of a stock option or warrant) whether now owned or hereafter acquired, (ii) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of any shares of the Issuer’s Common Stock, whether any such swap or transaction is to be settled by delivery of shares of the Issuer’s Common Stock or other securities, in cash or otherwise, (iii) make any demand for or exercise any right with respect to the registration of the Issuer’s Common Stock or any security convertible into or exercisable or exchangeable for Common Stock, or (iv) publicly announce the intention to do any of the foregoing.

    The foregoing description of the Lock-Up Agreement does not purport to be complete and is qualified in its entirety by reference to the Lock-Up Agreement, a copy of which is filed as Exhibit 6 to this Amendment No. 1 and is incorporated by reference in its entirety into this Item 6.

    Item 7. Material to Be Filed as Exhibits.

     

    Exhibit

    Number

      

    Exhibit Name

    5.    Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed by the Issuer on August 12, 2022)
    6.    Lock-Up Agreement


    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: August 17, 2022

     

    Squadron Capital LLC
    By:  

    /s/ David R. Pelizzon

      Name: David R. Pelizzon
      Title: President
    Squadron Capital Holdings LLC
    By:  

    /s/ Mary Parthe

      Name: Mary Parthe
      Title: Manager

    /s/ Jennifer N. Pritzker

    Jennifer N. Pritzker

    /s/ David R. Pelizzon

    David R. Pelizzon

    [Signature Page to Amendment No. 1 Schedule 13D]

    Get the next $KIDS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KIDS

    DatePrice TargetRatingAnalyst
    4/7/2025$37.00Buy
    Lake Street
    1/25/2024$39.00 → $31.00Buy → Hold
    Truist
    3/3/2022$83.00 → $65.00Buy
    Needham
    12/22/2021$75.00 → $68.00Buy
    BTIG
    12/21/2021$78.00 → $75.00Buy
    Truist Securities
    8/6/2021$70.00 → $77.00Market Outperform
    JMP Securities
    More analyst ratings

    $KIDS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • OrthoPediatrics Corp. Reports First Quarter 2025 Financial Results and Increases Full Year 2025 Revenue Guidance

      WARSAW, Ind., May 07, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial results for the first quarter ended March 31, 2025. First Quarter 2025 and Business Highlights Helped a record of nearly 39,000 children in the first quarter of 2025Generated total revenue of $52.4 million for the first quarter of 2025, up 17% from $44.7 million in first quarter 2024; domestic revenue increased 19% and international revenue increased 11% in the quarterGrew worldwide Trauma & Deformity revenue 14% and worldwide Scoliosis revenue 34% in the first

      5/7/25 4:05:00 PM ET
      $KIDS
      Medical/Dental Instruments
      Health Care
    • OrthoPediatrics Corp. Expands Trauma and Deformity Portfolio with 3P™ Pediatric Plating Platform™ Hip System

      WARSAW, Ind., May 07, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the expansion of its Trauma and Deformity portfolio with 3P™ Pediatric Plating Platform™ Hip System, the first of several systems in the 3P family. This represents the company's 5th FDA approval in 2025. 3P Pediatric Plating Platform Hip System is a new plate and screw platform to modernize and revolutionize trauma and deformity correction treatment in the lower extremities. This family of plating systems will provide surgeons unparalleled coverage for a variety of Trauma and

      5/7/25 4:01:00 PM ET
      $KIDS
      Medical/Dental Instruments
      Health Care
    • OrthoPediatrics Corp. to Report First Quarter Financial Results on May 7, 2025

      WARSAW, Ind., April 23, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (Nasdaq: KIDS a company focused exclusively on advancing the field of pediatric orthopedics, today announced that the Company is scheduled to release its first quarter 2025 financial results on May 7, 2025 after the market closes. OrthoPediatrics will host a conference call on Wednesday, May 7, 2025 at 4:30 p.m. ET to discuss the results. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.orthopediatrics.com, on the Investors page in the Events & Presentations section. The webcast will be available for repl

      4/23/25 4:05:00 PM ET
      $KIDS
      Medical/Dental Instruments
      Health Care

    $KIDS
    Financials

    Live finance-specific insights

    See more
    • OrthoPediatrics Corp. Reports First Quarter 2025 Financial Results and Increases Full Year 2025 Revenue Guidance

      WARSAW, Ind., May 07, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial results for the first quarter ended March 31, 2025. First Quarter 2025 and Business Highlights Helped a record of nearly 39,000 children in the first quarter of 2025Generated total revenue of $52.4 million for the first quarter of 2025, up 17% from $44.7 million in first quarter 2024; domestic revenue increased 19% and international revenue increased 11% in the quarterGrew worldwide Trauma & Deformity revenue 14% and worldwide Scoliosis revenue 34% in the first

      5/7/25 4:05:00 PM ET
      $KIDS
      Medical/Dental Instruments
      Health Care
    • OrthoPediatrics Corp. to Report First Quarter Financial Results on May 7, 2025

      WARSAW, Ind., April 23, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (Nasdaq: KIDS a company focused exclusively on advancing the field of pediatric orthopedics, today announced that the Company is scheduled to release its first quarter 2025 financial results on May 7, 2025 after the market closes. OrthoPediatrics will host a conference call on Wednesday, May 7, 2025 at 4:30 p.m. ET to discuss the results. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.orthopediatrics.com, on the Investors page in the Events & Presentations section. The webcast will be available for repl

      4/23/25 4:05:00 PM ET
      $KIDS
      Medical/Dental Instruments
      Health Care
    • OrthoPediatrics Corp. Reports Fourth Quarter and Full Year 2024 Financial Results

      Record full year 2024 revenue of $204.7 million increased 38% compared to prior year, and more than doubled fourth quarter 2024 adjusted EBITDA WARSAW, Ind., March 04, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, announced today its financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter and Full Year 2024 & Recent Business Highlights Helped a new record of over 34,000 children in the fourth quarter 2024 and approximately 138,000 for full year 2024, bringing the total to over 1.14 million since the i

      3/4/25 4:05:00 PM ET
      $KIDS
      Medical/Dental Instruments
      Health Care

    $KIDS
    Leadership Updates

    Live Leadership Updates

    See more
    • OrthoPediatrics Corp. Joins Crossroads Pediatric Device Consortium to Advance Pediatric Medical Device Innovation

      WARSAW, Ind., March 17, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, announced today its partnership with the Crossroads Pediatric Device Consortium (CPDC). This collaboration aligns with the Company's cause of improving the lives of children by supporting the development and commercialization of innovative pediatric medical devices.​ The Crossroads Pediatric Device Consortium is a multi-institutional initiative focused on accelerating the development, approval, and availability of medical devices designed specifically for pediatric patients. Founding member

      3/17/25 4:05:00 PM ET
      $KIDS
      Medical/Dental Instruments
      Health Care
    • OrthoPediatrics Joins Alliance for Pediatric Device Innovation

      WARSAW, Ind., Oct. 12, 2023 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS) a company focused exclusively on advancing the field of pediatric orthopedics, has announced a strategic partnership with Children's National Hospital in Washington, DC under the "Alliance for Pediatric Device Innovation" (APDI), to advice the development and commercialization of medical devices designed for children. Along with Children's National, APDI consortium members include Johns Hopkins University, CIMIT at Mass General Brigham, Tufts Medical Center and Medstar Health Research Institute. The Company will serve as APDI's strategic advisor and role model for devic

      10/12/23 8:05:00 AM ET
      $KIDS
      Medical/Dental Instruments
      Health Care
    • FzioMed Appoints Industry Veteran Paul Mraz as New President and CEO

      New CEO Paul Mraz also joins FzioMed Inc.'s Board of Directors;  Company set to accelerate growth of market leading Oxiplex® adhesion barrier products. SAN LUIS OBISPO, Calif., Jan. 3, 2023 /PRNewswire/ -- FzioMed, Inc. ("FzioMed" or the "Company"), a global leading surgical biomaterials company focused on spine/orthopedic, peritoneal and gynecological surgery, today announced the appointment of industry veteran Paul Mraz as its new President and CEO and member of the Board of Directors. Mraz's appointment became effective Jan. 1, 2023, commensurate with the retirement of John Krelle who served in the leadership role since 2005. "On behalf of the Board of Directors, I want to thank John for

      1/3/23 12:20:00 PM ET
      $KIDS
      Medical/Dental Instruments
      Health Care

    $KIDS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Lake Street initiated coverage on OrthoPediatrics with a new price target

      Lake Street initiated coverage of OrthoPediatrics with a rating of Buy and set a new price target of $37.00

      4/7/25 8:25:17 AM ET
      $KIDS
      Medical/Dental Instruments
      Health Care
    • OrthoPediatrics downgraded by Truist with a new price target

      Truist downgraded OrthoPediatrics from Buy to Hold and set a new price target of $31.00 from $39.00 previously

      1/25/24 7:05:43 AM ET
      $KIDS
      Medical/Dental Instruments
      Health Care
    • Needham reiterated coverage on OrthoPediatrics with a new price target

      Needham reiterated coverage of OrthoPediatrics with a rating of Buy and set a new price target of $65.00 from $83.00 previously

      3/3/22 11:28:34 AM ET
      $KIDS
      Medical/Dental Instruments
      Health Care

    $KIDS
    SEC Filings

    See more
    • SEC Form 10-Q filed by OrthoPediatrics Corp.

      10-Q - ORTHOPEDIATRICS CORP (0001425450) (Filer)

      5/8/25 3:37:15 PM ET
      $KIDS
      Medical/Dental Instruments
      Health Care
    • OrthoPediatrics Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - ORTHOPEDIATRICS CORP (0001425450) (Filer)

      5/7/25 4:14:08 PM ET
      $KIDS
      Medical/Dental Instruments
      Health Care
    • OrthoPediatrics Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ORTHOPEDIATRICS CORP (0001425450) (Filer)

      5/7/25 4:07:47 PM ET
      $KIDS
      Medical/Dental Instruments
      Health Care

    $KIDS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • General Counsel and Secretary Gerritzen Daniel J was granted 38,773 shares and sold $132,007 worth of shares (5,310 units at $24.86), increasing direct ownership by 43% to 110,767 units (SEC Form 4)

      4 - ORTHOPEDIATRICS CORP (0001425450) (Issuer)

      3/18/25 2:51:42 PM ET
      $KIDS
      Medical/Dental Instruments
      Health Care
    • President and CEO Bailey David R was granted 97,496 shares and sold $164,573 worth of shares (6,620 units at $24.86), increasing direct ownership by 40% to 319,155 units (SEC Form 4)

      4 - ORTHOPEDIATRICS CORP (0001425450) (Issuer)

      3/18/25 2:50:36 PM ET
      $KIDS
      Medical/Dental Instruments
      Health Care
    • COO and CFO Hite Fred sold $160,173 worth of shares (6,443 units at $24.86) and was granted 63,342 shares, increasing direct ownership by 38% to 207,989 units (SEC Form 4)

      4 - ORTHOPEDIATRICS CORP (0001425450) (Issuer)

      3/18/25 2:48:44 PM ET
      $KIDS
      Medical/Dental Instruments
      Health Care

    $KIDS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by OrthoPediatrics Corp.

      SC 13G/A - ORTHOPEDIATRICS CORP (0001425450) (Subject)

      11/14/24 1:34:08 PM ET
      $KIDS
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by OrthoPediatrics Corp. (Amendment)

      SC 13G/A - ORTHOPEDIATRICS CORP (0001425450) (Subject)

      5/8/24 2:22:57 PM ET
      $KIDS
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by OrthoPediatrics Corp. (Amendment)

      SC 13G/A - ORTHOPEDIATRICS CORP (0001425450) (Subject)

      2/14/24 3:33:43 PM ET
      $KIDS
      Medical/Dental Instruments
      Health Care